A feasibility study of induction pemetrexed plus cisplatin followed by extrapleural pneumonectomy and postoperative hemithoracic radiation for malignant pleural mesothelioma.

A prospective multi-institutional study has been commenced in Japan to evaluate the feasibility of induction chemotherapy using pemetrexed plus cisplatin, followed by extrapleural pneumonectomy (EPP) and postoperative hemithoracic radiation in patients with resectable malignant pleural mesothelioma. The study was initiated on May 2008 and 40 patients will be recruited over 3 years. Primary endpoints are macroscopic complete resection rate by EPP and treatment-related mortality for trimodality therapy. Secondary endpoints include treatment completion rate, adverse events, response rate by chemotherapy and 2-year overall and relapse-free survival.

[1]  C. Obasaju,et al.  A multicenter U.S. trial of neoadjuvant pemetrexed plus cisplatin (PC) followed by extrapleural pneumonectomy (EPP) and hemithoracic radiation (RT) for stage I-III malignant pleural mesothelioma (MPM) , 2007 .

[2]  K. Rosenzweig,et al.  Induction Chemotherapy, Extrapleural Pneumonectomy, and Postoperative High-Dose Radiotherapy for Locally Advanced Malignant Pleural Mesothelioma: A Phase II Trial , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[3]  D. Sugarbaker Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma. , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  D. Waller,et al.  Extra-pleural pneumonectomy for malignant pleural mesothelioma: the risks of induction chemotherapy, right-sided procedures and prolonged operations. , 2005, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[5]  R. Stahel,et al.  Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Byrne,et al.  Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Claude Denham,et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Ghielmini,et al.  The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  W. Richards,et al.  Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. , 1999, The Journal of thoracic and cardiovascular surgery.

[10]  D. Sugarbaker,et al.  Extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma. , 1992, The Annals of thoracic surgery.